Rapport Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of next-generation immuno-oncology therapies. Leveraging its proprietary ARCas (Allele-Rich Cell Assay Screening) platform, the company aims to identify and optimize fully human monoclonal antibodies and multispecific formats that selectively modulate both innate and adaptive immune pathways. Rapport’s pipeline targets novel checkpoints and costimulatory receptors to enhance anti-tumor responses while minimizing off-target toxicity.
The ARCas discovery engine integrates high-throughput single-cell screening with CRISPR-mediated target validation, enabling rapid identification of lead antibody candidates. In 2022, Rapport expanded its platform capabilities through the acquisition of Adagene’s Integrum™ Fc-engineering technology, adding tailored Fc modifications and multispecific scaffolds to its repertoire. The combined platforms support a growing preclinical portfolio that includes bispecific T-cell engagers, agonists for co-stimulatory receptors, and innate immune modulators.
Founded in 2017 as Cullinan Oncology, the company rebranded to Rapport Therapeutics following its strategic platform merger and Nasdaq listing under the ticker RAPP. Headquartered in San Francisco with additional facilities in New York, Rapport is backed by leading life-science investors and maintains collaborations with academic cancer centers and contract research organizations. The senior management team comprises seasoned executives and scientists with extensive experience in biologics development, translational immunology, and regulatory strategy.
Rapport’s research and development efforts are primarily centered in North America, with ongoing partnerships and research alliances in Europe and the Asia-Pacific region. The company is advancing its lead candidates toward Investigational New Drug (IND) filings and anticipates initiating first-in-human studies to evaluate safety, pharmacokinetics, and early signals of clinical activity in solid tumors and hematological malignancies.
AI Generated. May Contain Errors.
